Home › NDC Lookup › RxCUI directory › RxCUI 1801835

Lifitegrast 50 MG/ML Ophthalmic Solution — RxCUI 1801835

RxNorm drug concept · Semantic clinical drug
RxCUI 1801835 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1801835
Official nameLifitegrast 50 MG/ML Ophthalmic Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aslifitegrast 5 % Ophthalmic Solution
FDA products mapped3
Package NDCs mapped5
Reported Medicaid activity (SDUD)109,594 prescriptions · 49 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lifitegrast Ophthalmic: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • No, Xiidra is quite different from artificial tears. It's a prescription eye drop specifically designed to treat dry eye disease by reducing inflammation on the surface of your eye...
  • What is Xiidra actually for — is it just artificial tears?
  • That strange taste — often described as bitter or unpleasant — is one of the most commonly reported side effects of Xiidra, affecting anywhere from about 5 to 25 out of 100 people....
  • Why do I get a weird taste in my mouth after using the drops?
📖 Read our full Lifitegrast Ophthalmic guide →

🕸️ Concept Web — How Lifitegrast 50 MG/ML Ophthalmic Solution Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Lifitegrast 50 MG/ML Ophthalmic Solution RxCUI 1801835

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Lifitegrast 1801820
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Xiidra 1801836
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Lifitegrast Ophthalmic Solution 1801834
    • Lifitegrast Ophthalmic Product 1801833
    • Lifitegrast Ophthalmic Solution [Xiidra] 1801838
    • Xiidra Ophthalmic Product 1801839
    • Ophthalmic Solution 7670
    • Ophthalmic Product 1151135
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Lifitegrast 50 MG/ML SCDC · 1801832
  • Lifitegrast Ophthalmic Solution SCDF · 1801834
  • Lifitegrast Ophthalmic Product SCDG · 1801833

Brand-Name Concepts

📦 FDA Products & Package NDCs

3 products · 5 package NDCs
5 package NDCs map to RxCUI 1801835 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00078-0911-12 12 POUCH in 1 CARTON (0078-0911-12) / 5 AMPULE in 1 POUCH (... Xiidra Novartis Pharmaceuticals Corporation 2020-06-04
00078-0911-94 4 POUCH in 1 CARTON (0078-0911-94) / 5 AMPULE in 1 POUCH (0... Xiidra Novartis Pharmaceuticals Corporation 2020-06-04
24208-0911-12 12 POUCH in 1 CARTON (24208-911-12) / 5 AMPULE in 1 POUCH (... Xiidra Bausch & Lomb Incorporated 2024-01-02
24208-0911-94 4 POUCH in 1 CARTON (24208-911-94) / 5 AMPULE in 1 POUCH (2... Xiidra Bausch & Lomb Incorporated 2024-01-02
59651-0450-60 60 POUCH in 1 CARTON (59651-450-60) / 5 AMPULE in 1 POUCH (... Lifitegrast Aurobindo Pharma Limited 2023-11-07
Observed labelers: Bausch & Lomb Incorporated (2) · Novartis Pharmaceuticals Corporation (2) · Aurobindo Pharma Limited (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.